CagriSema
5 articles on CagriSema, written by Shotlee and medically reviewed for clinical accuracy.
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Novo Nordisk Investigated Over CagriSema Trial Results - NVO
Novo Nordisk faces an investor investigation by DJS Law Group over claims of misleading statements about its CagriSema weight loss drug trial. The phase 3 study failed to demonstrate non-inferiority against Eli Lilly's tirzepatide after 84 weeks, triggering a sharp 15%+ premarket stock plunge on February 23, 2026. Investors affected by the drop may have rights under securities laws.
5 min read
New GLP-1 Weight-Loss Drugs Stronger Than Wegovy and Zepbound
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
8 min read
CagriSema Superior to Semaglutide for HbA1c, Weight Loss in T2D
New topline data from the REIMAGINE 2 trial reveal CagriSema outperforms semaglutide in HbA1c reduction and weight loss for adults with type 2 diabetes inadequately controlled on metformin. Patients on CagriSema 2.4mg/2.4mg saw a 1.91% point HbA1c drop and 14.2% body weight loss at 68 weeks. This combination of cagrilintide and semaglutide sets a new benchmark in T2D therapy.
6 min read